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Abstract
Background—Unsafe medical injections remain a potential route of HIV transmission in Kenya. 
We used data from a national survey in Kenya to study the magnitude of medical injection use, 
medication preference, and disposal of medical waste in the community.
Methods—The Kenya AIDS Indicator Survey 2012 was a nationally representative population-
based survey. Among participants aged 15–64 years, data were collected regarding medical 
injections received in the year preceding the interview; blood samples were collected from 
participants for HIV testing.
Results—Of the 13,673 participants who answered questions on medical injections, 35.9% [95% 
confidence interval (CI): 34.5 to 37.3] reported receiving ≥1 injection in the past 12 months and 
51.2% (95% CI: 49.7 to 52.8) preferred receiving an injection over a pill. Among those who 
received an injection from a health care provider, 95.9% (95% CI: 95.2 to 96.7) observed him/her 
open a new injection pack, and 7.4% (95% CI: 6.4 to 8.4) had seen a used syringe or needle near 
their home or community in the past 12 months. Men who had received ≥1 injection in the past 12 
months (adjusted odds ratio, 3.2; 95% CI: 1.2 to 8.9) and women who had received an injection in 
the past 12 months, not for family planning purposes (adjusted odds ratio, 2.6; 95% CI: 1.2 to 5.5), 
were significantly more likely to be HIV infected compared with those who had not received 
medical injection in the past 12 months.
Conclusions—Injection preference may contribute to high rates of injections in Kenya. 
Exposure to unsafe medical waste in the community poses risks for injury and infection. We 
recommend that community- and facility-based injection safety strategies be integrated in disease 
prevention programs.
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INTRODUCTION
Medical injections, if given safely, can save lives by preventing and treating disease. Each 
year, at least 16 billion injections are administered in low- and middle-income countries, but 
over half of these injections have been shown to be either unnecessary or unsafe.1–4 Unsafe 
injections can cause bacterial infections leading to abscesses and septicemia.1 Additionally, 
they are important routes of transmission of blood-borne pathogens.2 These pathogens 
include hepatitis B virus, hepatitis C virus, HIV, malaria, trypanosomiases, and viral 
hemorrhagic fever viruses. In 2000, it was estimated that unsafe medical injections led to 
260,000 HIV infections, 2 million hepatitis C virus infections, and 21 million hepatitis B 
virus infections globally.5
Poor disposal of contaminated needles and syringes and other medical waste poses a risk to 
health care providers, patients, and the community.6 Traditionally, most health programs 
have concentrated their efforts on disposal of syringes and needles within the health care 
settings.7 With expansion of health services and overwhelmed health facility waste 
management systems, there is increased disposal of medical waste, including contaminated 
needles and syringes, in the community.6–8 This has led to increases in risk of injury to 
community members, especially children and domestic waste handlers.9 Whereas 
industrialized countries such as the United States of America, Canada, and Australia have 
community-based programs for needle and syringe disposal,10 this is not the case in most 
low- and middle-income countries, including Kenya.
The Kenya Ministry of Health recognizes that administration of unsafe and unnecessary 
injections and inappropriate disposal of the medical waste are health challenges.11 In 2008, 
it was estimated that 2.2% of new HIV infections in Kenya were a result of unsafe injections 
received in health facilities.12 The first Kenya AIDS Indicator Survey (KAIS 2007) reported 
that 33% of adults and adolescents aged 15–64 years had received at least 1 injection within 
the 12 months preceding the survey and that about 50% preferred injections over oral 
medications.13 Furthermore, there was a corresponding increase in HIV prevalence with 
increasing number of medical injections reported.
Since 2004, the Ministry of Health has implemented several strategies to address injection 
safety, including health care provider trainings, behavior change communication, and 
community education on the dangers of unsafe and unnecessary injections.11 It has also 
educated the public on its role in ensuring safe injections and preventing re-use among 
patients by confirming that the injection device used is new.14 However, many people 
remain unaware of the increased health risks associated with unsafe administration of 
injections.14
Despite the ongoing interventions, no population-based data on injection preference, 
injection usage, and medical waste disposal in the community have been collected since 
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KAIS 2007. The second Kenya AIDS Indicator Survey (KAIS 2012) presented an 
opportunity to obtain current information on medical injection safety and medical waste 
disposal, allowing for an assessment of trends over the past 5 years.
METHODS
Study Design and Study Population
KAIS 2012 was a stratified 2-stage cluster population-based survey designed to generate 
national and sub-national estimates of HIV-related indicators among Kenyans aged 18 
months to 64 years. The survey methods for KAIS 2012 are described in detail elsewhere.15 
Briefly, individual questionnaires were administered to adults and adolescents aged 15–64 
years that collected information on sociodemographic characteristics, behaviors, and access 
to health care services, including medical injection practices, injection safety, and medical 
waste disposal. Participants were asked to provide blood samples for HIV testing at a central 
laboratory. Participants were informed that their HIV test results from the laboratory would 
not be returned to them. However, they were offered home-based HIV testing and 
counseling to learn their HIV status in the home using rapid HIV test kits according to the 
Kenyan national HIV testing and counseling protocol.15 In this article, we present a 
subanalysis of KAIS 2012 to describe medical injection use, medication preferences, and 
reports of unsafe medical waste disposal in the community among Kenyan adults and 
adolescents aged 15–64 years.
Measurements
We had three outcome variables of interest: history of medical injection in the past 12 
months, medication preference, and HIV infection. Previous history of medical injection 
was based on the question, “Have you had an injection for any reason in the last 12 
months?” For female participants, we also based history of medical injection on the 
question, “Are you currently using any method to delay or avoid getting pregnant?” Those 
who answered “Yes-injectable method” and had not been captured in the question above 
were classified as having a history of medical injection in the past 12 months. Predictor 
variables for history of medical injection in the past 12 months included sex, age, marital 
status, level of education, area of residence, region, household wealth index, and medication 
preference. Medication preference was based on the question: “If you had a choice, would 
you like to receive medication as an injection or a pill?” Predictor variables for medication 
preference included demographic variables and history of medical injection in the past 12 
months, number of injections, and use of injectable family planning method. HIV status was 
based on the laboratory-confirmed HIV results at the central laboratory. The predictor 
variables for HIV infection were age, injection history, use of injectable contraceptives (for 
women only), the number of injections received in the past 12 months, and whether the 
injection was self-administered.
Laboratory Measurements
Participants were requested to provide a blood specimen for HIV testing at the National HIV 
Reference Laboratory in Nairobi. Specimens were tested for HIV antibody using the 
Vironostika HIV-1/2 UNIF II Plus O Enzyme Immunoassay (bioMérieux, Marcy d’Etoile, 
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France), and positive results were confirmed using the Murex HIV.1.2.O HIV Enzyme 
Immunoassay (DiaSorin, SpA, Saluggia, Italy). Repeat testing was performed for discordant 
results using the same algorithm, and if results remained discordant, final results were 
obtained using polymerase chain reaction (Cobas Amplicor HIV-1 Monitor Test, version 
1.5, Roche Molecular Diagnostics, Pleasanton, CA).
Data Management and Analysis
Data were collected at the point of interview using netbook computers (Mirus Innovations, 
Mississauga, Ontario, Canada). Data collected in the household were transmitted through a 
secure wireless network to a central database in Nairobi where data merging, cleaning, and 
weighting were performed before analysis. Statistical analyses were performed using survey 
procedures in STATA version 12.0 (STATA Corporation, College Station, TX) and SAS 
version 9.3 (SAS Institute Inc., Cary, NC). We conducted descriptive analyses to describe 
persons who had received a medical injection in the past 12 months by select demographic 
and injection-specific characteristics and present results as weighted population proportions 
and 95% confidence intervals (CI). We conducted bivariate analyses to estimate the 
frequencies and proportions of receiving injections in the past 12 months, medication 
preference, and HIV infection by select variables. Using variables that had a P value <0.1 in 
the bivariate anlayses, we also conducted multivariable analyses to determine factors 
independently associated with receiving injections in the past 12 months and medication 
preference. Estimates for measures of association are presented as odds ratios, adjusted odds 
ratios (aOR), and 95% CI. All analyses were weighted to account for sampling probability 
and to adjust for survey nonresponse.
Ethical Considerations
The survey protocol, survey collection tools, and consent procedures were approved by the 
Kenya Medical Research Institute (KEMRI) Ethical Review Committee, the US Centers for 
Disease Control and Prevention (CDC) Institutional Review Board, and the Committee on 
Human Research of the University of California, San Francisco (UCSF).
RESULTS
A total of 13,720 adults and adolescents aged 15–64 years participated in the survey. Of 
these, 13,673 (99.7%) completed the question on having received or not received an medical 
injection for any reason in the previous 12 months; 7928 (51.0%) of these were women, and 
5745 (49.0%) were men.
History of Medical Injection in the Previous 12 Months
In total, 4906 (35.9%, 95% CI: 34.5 to 37.3) had received at least 1 medical injection in the 
previous 12 months. Among those, 63.6% (95% CI: 61.9 to 65.4) were women (Table 1). 
Over 60% were married or cohabiting (64.2%, 95% CI: 62.5 to 65.9), lived in rural 
residences (62.1%, 95% CI: 59.5 to 64.6), and aged less than 35 years, including 32.0% 
(95% CI: 30.5 to 33.4) of those aged 15–24 years and 32.8% (95% CI: 31.3 to 34.2) of those 
aged 25–34 years. Injection recipients were evenly distributed by household wealth index 
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with 17.3% (95% CI: 15.0 to 19.7) in the poorest and 20.3% (95% CI: 17.6 to 23.0) in the 
richest wealth index quintile.
Among respondents who reported receiving at least 1 injection in the previous 12 months, 
96.3% (95% CI: 95.5 to 97.1) were administered by health care providers, 4.6% (95% CI: 
3.5 to 5.7) were self-administered, and 0.4% (95% CI: 0.2 to 0.7) were administered by 
traditional practitioners. Injectable contraceptives accounted for 42.2% (95% CI: 40.0 to 
44.4) of all medical injections administered to women (data not shown). The vast majority 
of respondents (95.9%, 95% CI: 95.2 to 96.7) reported that the last time they received an 
injection from a health care provider, the needle came from a new, unopened package. Half 
(50.2%, 95% CI: 48.4 to 52.0) preferred injections as medication, 36.5% (95% CI: 34.8 to 
38.3) preferred pills, and 13.3% (95% CI: 12.1 to 14.4) had no treatment preference. Seven 
percent of injection recipients (7.4%, 95% CI: 6.4 to 8.4) had seen a used needle or syringe 
near their home or community in the past 12 months compared with 6.3% (95% CI: 5.5 to 
7.0) of all survey respondents. In total, 14,982 injections received by participants were 
administered by health care providers in the previous 12 months, corresponding to an 
average of 3.6 injections per person among those that received at least 1 injection in the past 
year. When applied to the survey population, the per capita medical injection rate for adults 
and adolescents aged 15–64 years was 1.1 injections per person per year.
In multivariate analyses, factors independently associated with increased odds of receiving a 
medical injection in the previous 12 months were being a woman (aOR, 2.1; 95% CI: 1.8 to 
2.3); being currently or previously married or cohabiting compared with being never married 
or cohabiting [married or cohabiting (aOR, 2.2; 95% CI: 1.9 to 2.5); ever widowed (aOR, 
1.7; 95% CI: 1.4 to 2.2); and separated/divorced (aOR, 1.7; 95% CI: 1.3 to 2.2)]; living in 
Nyanza (aOR, 1.6; 95% CI: 1.2 to 2.0) and Western (aOR, 1.4; 95% CI: 1.1 to 1.8) regions 
compared with Nairobi region; increasing education levels compared with having no 
primary education [incomplete primary (aOR, 1.7; 95% CI: 1.2 to 2.2); complete primary 
(aOR, 1.5; 95% CI: 1.2 to 1.9); and secondary or higher level of education (aOR, 1.4; 95% 
CI: 1.1 to 1.8)]; and being in the middle (aOR, 1.3; 95% CI: 1.1 to 1.6) or fourth highest 
(aOR, 1.3; 95% CI: 1.1 to 1.6) wealth quintile compared with being in the poorest wealth 
quintile (Table 2). Compared with persons aged 15–24 years, persons aged 35–64 years had 
significantly lower odds of receiving an injection in the past 12 months [aged 35–44 years 
(aOR, 0.7; 95% CI: 0.6 to 0.8), aged 45–54 years (aOR, 0.6; 95% CI: 0.5 to 0.7), and aged 
55–64 years (aOR, 0.5; 95% CI: 0.4 to 0.7)]. We also examined these associations separately 
for men and women and found similar results (data not shown).
Medication Preference
Overall, 51.2% (95% CI: 49.7 to 52.8) of survey participants preferred an injection to a pill 
as medication (Table 3). Preference for injection was higher among women (56.7%, 95% 
CI: 54.9 to 58.5) than men (45.3%, 95% CI: 43.4 to 47.2). Preference for injection was 
highest among persons aged 25–34 years, at 56.2% (95% CI: 54.0 to 58.4) and decreased 
with increasing age to a low of 45.4% (95% CI: 41.4 to 49.4) for persons aged 55–64 years. 
Over half of those who preferred injections resided in rural areas (51.6%, 95% CI: 49.8 to 
53.4), were married or cohabiting (54.6%, 95% CI: 52.9 to 56.3), and had completed 
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primary education (52.2%, 95% CI: 50.1 to 54.3). Preference for injection was higher 
among those who had received at least 1 injection in the previous 12 months (57.9%, 95% 
CI: 55.9 to 59.8) compared with those who had received no injection during the same time 
period (47.3%, 95% CI: 45.6 to 49.0).
In multivariate analyses, older respondents aged 35–44 years (aOR, 0.8; 95% CI: 0.7 to 0.9), 
45–54 years (aOR, 0.7, 95% CI: 0.6 to 0.8), and 55–64 years (aOR, 0.6, 95% CI: 0.5 to 0.7) 
had lower odds of preferring an injection to a pill for medication than younger respondents 
aged 15–24 years. Female sex (aOR, 1.5; 95% CI: 1.3 to 1.6), residing in urban areas (aOR, 
1.2; 95% CI: 1.1 to 1.4), and receiving an injection in the previous 12 months (aOR, 1.4; 
95% CI: 1.3 to 1.5) were associated with a higher odds of preferring an injection to a pill.
Medication Injection and Associations With HIV Infection
HIV prevalence was 6.3% (95% CI: 5.1 to 7.4) among individuals who received at least 1 
injection in the past 12 months compared with 5.3% (95% CI: 4.6 to 5.9) among those who 
had not (data not shown). Among those who had received an injection from a traditional 
practitioner in the past 12 months, HIV prevalence was 20.6% (95% CI: 0 to 44.4). In 
contrast, HIV prevalence among persons who had self-administered an injection in the past 
12 months was 3.5% (95% CI: 0.4 to 6.6).
Among men, HIV prevalence among those who received a medical injection in the past 12 
months (5.8%, 95% CI: 4.2 to 7.3) was significantly higher than those who did not receive 
an injection (3.8%, 95% CI: 3.1 to 4.5) (Table 4). Men who had self-administered an 
injection in the past 12 months had low HIV prevalence at 2.6% (95% CI: 0 to 6.3). 
Although men who reported receiving 2 to 3 (6.0%, 95% CI: 3.6 to 8.3) and 4 or more 
(6.6%, 95% CI: 3.0 to 10.2) medical injections from a health care provider in the past 12 
months had higher HIV prevalence than men who had received no injections from health 
care providers (3.9%, 95% CI: 3.2 to 4.6), these differences were not statistically significant. 
After adjusting for age and number of injections received in the previous 12 months, men 
who had received a medical injection in the previous 12 months were 3 times more likely to 
be HIV infected than men who did not receive injections in the same time period (aOR, 3.2; 
95% CI: 1.2 to 8.9).
Among women, HIV prevalence was 7.1% (95% CI: 6.2 to 8.1) among those who had not 
received a medical injection in the past 12 months, 5.5% (95% CI: 4.1 to 7.0) among women 
who received injectable contraceptives, and 7.4% (95% CI: 5.8 to 8.9) among women who 
received medical injections for reasons other than family planning (Table 5). Women who 
self-administered a medical injection in the past 12 months had an HIV prevalence of 4.8% 
(95% CI: 0 to 10.0). No associations were observed between the number of injections 
received by a health care provider and HIV infection among women. After controlling for 
age and the number of injections administered by a health care worker in the past 12 months, 
women who received injections for reasons other than family planning purposes were 3 
times more likely to be HIV infected compared with women who received no injections in 
the past 12 months (aOR, 2.6; 95% CI: 1.2 to 5.5).
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In this nationally representative survey, we found that approximately one-third of adults 
aged 15–64 years had received a medical injection in the 12 months preceding the survey, 
and the vast majority of these had received injections from a health care provider. Those 
who received injections were mainly women, currently or previously married, with higher 
wealth and education, and residents of Nyanza and Western regions. The estimated number 
of injections from health care providers per person per year was 1.1 injections. A global 
average of 3.4 medical injections per person per year among children and adults has been 
reported elsewhere, with Africa reporting an average of 2.2 medical injections per person 
per year.1 The proportion of medical injection recipients in our study, however, remained 
similar to what was reported in KAIS 2007, where 1 in every 3 persons aged 15–64 years 
received at least 1 medical injection in the previous 12 months.13
We found that 1 in 15 participants had seen a used syringe or needle near their home or in 
their community in the past 12 months. This finding corroborates 2 recent studies reporting 
improper medical waste disposal in the community. Mazrui and colleagues16 found that 
11% of private health facilities in Nairobi disposed of medical waste in open dump sites, and 
a United Nations Environmental Program study team reported seeing used needles in the 
general waste disposal site in Dandora, Nairobi.17
Given a choice, half of Kenyan adults and adolescents preferred an injection to a pill for 
medication purposes, similar to what was reported in KAIS 2007.13 Furthermore, this rate 
was also similar to findings from a program evaluation of safe medical injections in Kenya, 
which showed that 5 out of 10 persons in Western and Nyanza regions preferred medical 
injections to pills.18 We also found that individuals who received an injection in the 
previous 12 months had significantly higher odds of preferring medical injections to pills 
compared with those who had no medication preference. These findings indicate that 
injection preference can influence injection use which could potentially lead to unnecessary 
and unsafe injections. Women were more likely than men to prefer injections over pills and 
accounted for 70% of medical injections that were administered by health care providers, 
with at least 40% for contraceptive purposes. This was consistent with findings from the 
Kenya Demographic and Health Survey of 2008–09, which reported that injectable 
contraceptives were the most widely used family planning method, with 1 in 5 women aged 
15–49 years reporting that they were currently using this method.19
Individuals who had received higher number of injections from a health care provider in the 
previous 12 months had similar odds of HIV infection compared with individuals who had 
received no injections from a health care provider in the same time frame. Both men and 
women who received medical injections in the 12 months preceding the survey (not for 
contraceptive purposes among women) were more likely to have been HIV infected than 
those who had not received any injections in the previous 12 months. High HIV prevalence 
was noted among persons who had received injections from traditional practitioners, though 
the number reporting this practice was small. There is a possibility of re-use of injection 
devices in traditional medicine settings, potentially increasing the risk of HIV transmission 
and acquisition. We were encouraged to find that over 95% of those who received injections 
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from health care providers observed a new, unopened needle package being opened. Patient-
observed sterile treatment is a national strategy that has been adopted in Kenya since 2004 to 
ensure sterile care and reduction in HIV transmission risk in health care settings.20
This study had several limitations. The analysis relied on self-reported data that may have 
been limited by recall bias. To minimize this bias, we restricted the recall period to the 
preceding 12 months from the survey. Second, variables on medical waste in the community 
were dependent on correct knowledge of a used syringe or needle, but no informational 
material was provided to survey participants to confirm visual understanding of medical 
waste. Therefore, our reported estimates on medical waste could be either an overestimate or 
underestimate of true values in the population. Because KAIS 2012 was a cross-sectional 
survey where potential predictors and outcomes were measured at the same time, we were 
not able to determine causality in associations observed, such as those reported for injection 
status and HIV infection. In addition, we did not collect information on whether medical 
injections received were curative or preventative, both of which may have impacted our 
estimates of injection history and injection preference. Finally, the number of self-
administered injections and number of injections received from traditional practitioners were 
not quantified, which may have contributed to lower injection totals.
Despite these limitations, this study provides important nationally representative population-
based data that can be used to inform the national program on targeted strategies for the 
prevention of medical transmission of HIV and other blood-borne pathogens. Efforts to 
improve health communication, particularly to those who are more likely to receive medical 
injections, are needed to reduce the risks of unsafe injections, to address the hazards of 
medical waste disposal in the community, and to educate traditional practitioners on safe 
injection practices. In addition, medical waste management programs need to support waste 
disposal at the health facility and the community. Finally, given the wide use of injectable 
contraceptives among women, we recommend that the national reproductive health program 
integrate injection safety practices in reproductive health services. These recommendations 
can form the basis for policy makers to support injection safety interventions for patients, 
health care providers, and the community as part of comprehensive infection prevention and 
control programs.
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TABLE 1
Select Characteristics Among Adults and Adolescents Aged 15–64 Years Reporting At Least 1 Medical 
Injection in Previous 12 Months, Kenya AIDS Indicator Survey 2012
Selected Characteristics
Received Injection in Previous 12 Months*
Unweighted, N Weighted % (95% CI)
Total 4906 –
Sex
 Men 1464 36.4 (34.6 to 38.1)
 Women 3442 63.6 (61.9 to 65.4)
Age group, yrs
 15–24 1588 32.0 (30.5 to 33.4)
 25–34 1608 32.8 (31.3 to 34.2)
 35–44 897 18.5 (17.3 to 19.6)
 45–54 509 10.7 (9.6 to 11.7)
 55–64 304 6.1 (5.4 to 6.8)
Marital status
 Never married/never cohabited 1113 23.4 (22.0 to 24.9)
 Married/cohabiting 3149 64.2 (62.5 to 65.9)
 Separated/divorced 295 5.9 (5.3 to 6.6)
 Ever widowed 348 6.5 (5.8 to 7.2)
Highest educational attainment
 No primary 420 6.0 (5.1 to 6.9)
 Incomplete primary 462 8.4 (7.3 to 9.5)
 Complete primary 1662 34.2 (32.5 to 36.0)
 Secondary or higher 2362 51.4 (49.4 to 53.4)
Residence
 Rural 3030 62.1 (59.5 to 64.6)
 Urban 1876 37.9 (35.4 to 40.5)
Region
 Nairobi 609 10.5 (9.3 to 11.7)
 Central 503 11.4 (9.9 to 12.8)
 Coast 550 8.2 (6.8 to 9.7)
 Eastern 830 14.8 (13.0 to 16.6)
 Nyanza 800 16.9 (14.7 to 19.0)
 Rift Valley 918 26.1 (23.4 to 28.9)
 Western 696 12.0 (10.5 to 13.5)
Household wealth index, quintiles
 Poorest 880 17.3 (15.0 to 19.7)
 Second 1047 20.8 (18.7 to 22.8)
 Middle 1041 21.1 (19.0 to 23.2)
 Fourth 982 20.5 (18.0 to 22.9)
 Richest 956 20.3 (17.6 to 23.0)
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Selected Characteristics
Received Injection in Previous 12 Months*
Unweighted, N Weighted % (95% CI)
No. injections received by health care provider in previous 12 months†
 0 167 3.7 (2.9 to 4.5)
 1 1324 32.6 (30.9 to 34.2)
 2–3 1693 39.5 (37.9 to 41.2)
 4+ 1067 24.2 (22.5 to 25.9)
Injection by traditional practitioner in previous 12 months†
 No 4881 99.6 (99.3 to 99.8)
 Yes 21 0.4 (0.2 to 0.7)
Self-administered injection in previous 12 months†
 No 4169 95.4 (94.3 to 96.5)
 Yes 196 4.6 (3.5 to 5.7)
Health care provider used a needle from a new, unopened package‡
 No 168 4.1 (3.3 to 4.8)
 Yes 4034 95.9 (95.2 to 96.7)
Medication preference
 Injection 2458 50.2 (48.4 to 52.0)
 Pills 1762 36.5 (34.8 to 38.3)
 Unsure/no preference 686 13.3 (12.1 to 14.4)
Had seen used needle/syringe near home or community in the previous 12 months
 No 4530 92.6 (91.6 to 93.6)
 Yes 359 7.4 (6.4 to 8.4)
*
Includes 537 women who reported current injectable contraceptive use but answered “no” to receiving injections in the last 12 months.
†
Excludes 537 women who reported current injectable contraceptive use but answered “no” to receiving injections in last 12 months and therefore 
not asked to quantify the number of injections received.
‡
Among those who received injections from a health care provider. Because of missing values, totals vary between variables.
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